尿失禁装置市場は、2024年の42億2000万ドルから2030年までに79億7000万ドルに成長し、予測期間中に11.2%のCAGRで成長すると予想されます。尿失禁装置市場における著名なプレーヤーには、Coloplast Corp (Denmark), B. Braun SE (Germany), Johnson & Johnson Services, Inc. (US), Convatec Inc. (UK), Boston Scientific Corporation (US), Hollister Incorporated (US), Becton, Dickinson and Company (BD) (US), Cook Group (US), Cardinal Health (US), Laborie (US), Medtronic (Ireland), Teleflex Incorporated (US).などがあります。
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONS CONSIDERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key sources for secondary data
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primary interviews
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Company revenue estimation approach
2.2.1.1.1 Presentations of companies and primary interviews
2.2.1.1.2 Primary interviews
2.2.1.1.3 US-based approach
2.2.2 TOP-DOWN APPROACH
2.3 DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS
2.5.1 STUDY ASSUMPTIONS
2.5.2 GROWTH RATE ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 URINARY INCONTINENCE DEVICES MARKET OVERVIEW
4.2 ASIA PACIFIC: URINARY INCONTINENCE DEVICES MARKET, BY PRODUCT & COUNTRY (2023)
4.3 GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 REGIONAL MIX: URINARY INCONTINENCE DEVICES MARKET, 2024 VS. 2030
4.5 URINARY INCONTINENCE DEVICES MARKET: DEVELOPED VS. EMERGING MARKETS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of urinary incontinence
5.2.1.2 Expanding geriatric population
5.2.1.3 Growing attention to personal hygiene
5.2.1.4 Advancements in home healthcare solutions
5.2.2 RESTRAINTS
5.2.2.1 Social stigma associated with incontinence care products
5.2.2.2 Environmental concerns related to disposal of urinary incontinence products
5.2.2.3 Potential side-effects & complications
5.2.3 OPPORTUNITIES
5.2.3.1 Technological advancements in urinary incontinence devices
5.2.3.2 Rapid urbanization and rising disposable income
5.2.4 CHALLENGES
5.2.4.1 Use of alternative treatment options
5.3 PRICING ANALYSIS
5.3.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.3.2 AVERAGE SELLING PRICE TREND, BY REGION
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 PORTER'S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 KEY STAKEHOLDERS & BUYING CRITERIA
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.8.2 KEY BUYING CRITERIA
5.9 REGULATORY LANDSCAPE
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9.2 REGULATORY FRAMEWORK
5.9.2.1 North America
5.9.2.1.1 US
5.9.2.1.2 Canada
5.9.2.2 Europe
5.9.2.3 Asia Pacific
5.9.2.3.1 China
5.9.2.3.2 Japan
5.9.2.3.3 India
5.9.2.4 Latin America
5.9.2.4.1 Brazil
5.9.2.4.2 Mexico
5.9.2.5 Middle East
5.9.2.6 Africa
5.10 TRADE ANALYSIS
5.10.1 IMPORT DATA FOR HS CODE 901839
5.10.2 EXPORT DATA FOR HS CODE 901839
5.11 PATENT ANALYSIS
5.11.1 LIST OF MAJOR PATENTS
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.14 TECHNOLOGY ANALYSIS
5.14.1 KEY TECHNOLOGIES
5.14.1.1 Surgical & implantable devices
5.14.2 COMPLEMENTARY TECHNOLOGIES
5.14.2.1 Electrical stimulation devices
5.15 INVESTMENT & FUNDING SCENARIO
5.16 IMPACT OF AI/GEN AI ON URINARY INCONTINENCE DEVICES MARKET
5.16.1 AI USE CASES
6 URINARY INCONTINENCE DEVICES MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 URINARY CATHETERS
6.2.1 INTERMITTENT CATHETERS
6.2.1.1 Reduced risk of infections to boost market
6.2.2 INDWELLING CATHETERS
6.2.2.1 Rising usage by critically ill patients to drive demand
6.2.3 EXTERNAL CATHETERS
6.2.3.1 Ease of use to boost market growth
6.3 VAGINAL & URETHRAL SLINGS
6.3.1 RISING PREVALENCE OF STRESS INCONTINENCE TO DRIVE GROWTH
6.4 ELECTRICAL STIMULATION DEVICES
6.4.1 GROWING PREFERENCE FOR ELECTRICAL STIMULATION DEVICES FOR TREATMENT OF OAB TO DRIVE GROWTH
6.5 ARTIFICIAL URINARY SPHINCTERS
6.5.1 REDUCED RISK OF INFECTIONS ASSOCIATED WITH ARTIFICIAL URINARY SPHINCTERS TO DRIVE ADOPTION
6.6 OTHER URINARY INCONTINENCE DEVICES
7 URINARY INCONTINENCE DEVICES MARKET, BY INCONTINENCE TYPE
7.1 INTRODUCTION
7.2 STRESS INCONTINENCE
7.2.1 GROWING PREVALENCE OF STRESS INCONTINENCE TO DRIVE MARKET GROWTH
7.3 URGE INCONTINENCE
7.3.1 CONTINUOUS INNOVATIONS TO SUSTAIN MARKET GROWTH
7.4 MIXED INCONTINENCE
7.4.1 GROWING AWARENESS AMONG BOTH PATIENTS AND HEALTHCARE PROVIDERS TO BOOST MARKET GROWTH
7.5 OVERFLOW INCONTINENCE
7.5.1 AGING POPULATION AND ASSOCIATED UROLOGICAL CONDITIONS TO DRIVE MARKET DEMAND
7.6 FUNCTIONAL INCONTINENCE
7.6.1 MOBILITY DISORDERS TO SUSTAIN MARKET GROWTH
8 URINARY INCONTINENCE DEVICES MARKET, BY PATIENT TYPE
8.1 INTRODUCTION
8.2 FEMALE PATIENTS
8.2.1 HIGHER RATE OF URINARY INCONTINENCE IN FEMALES TO DRIVE MARKET
8.3 MALE PATIENTS
8.3.1 RISING PREVALENCE OF BPH TO PROPEL MARKET GROWTH
9 URINARY INCONTINENCE DEVICES MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS
9.2.1 LARGE VOLUME OF SURGICAL PROCEDURES TO DRIVE GROWTH
9.3 PHYSICIANS' OFFICES
9.3.1 EXPERTISE OF PROFESSIONALS IN TREATMENT OF URINARY INCONTINENCE TO PROPEL GROWTH
9.4 OTHER END USERS
10 URINARY INCONTINENCE DEVICES MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 Favorable healthcare initiatives for prevention of UI to drive market
10.2.3 CANADA
10.2.3.1 Increasing geriatric population to drive market growth
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Rising healthcare expenditure to propel market
10.3.3 UK
10.3.3.1 Rising prevalence of chronic diseases to support market growth
10.3.4 FRANCE
10.3.4.1 Large target population to boost demand
10.3.5 ITALY
10.3.5.1 Rising geriatric population and subsequent rise in UI to drive market
10.3.6 SPAIN
10.3.6.1 Uptake of advanced technologies for UI treatment to support market growth
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 CHINA
10.4.2.1 Growing focus on preventive care due to large target patient pool to boost demand
10.4.3 JAPAN
10.4.3.1 Presence of established healthcare system and favorable reimbursements to drive market
10.4.4 INDIA
10.4.4.1 Rising cases of urinary incontinence and increasing healthcare investments to propel market
10.4.5 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Favorable reimbursement scenario for medical device manufacturers to drive market
10.5.3 MEXICO
10.5.3.1 Rising demand for advanced UI products to drive market
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN URINARY INCONTINENCE DEVICES MARKET
11.3 REVENUE ANALYSIS, 2019-2023
11.4 MARKET SHARE ANALYSIS, 2023
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
11.5.5.2 Region footprint
11.5.5.3 Product footprint
11.5.5.4 Patient type footprint
11.5.5.5 End-user footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.6.5.1 Detailed list of key startup/SME players
11.6.5.2 Competitive benchmarking of key emerging players/startups
11.7 COMPANY VALUATION & FINANCIAL METRICS
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES & APPROVALS
11.9.2 DEALS
11.9.3 EXPANSIONS
11.9.4 OTHER DEVELOPMENTS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 COLOPLAST CORP.
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Recent developments
12.1.1.3.1 Product launches
12.1.1.3.2 Expansions
12.1.1.4 MnM view
12.1.1.4.1 Key strengths
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses & competitive threats
12.1.2 B. BRAUN SE
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 MnM view
12.1.2.3.1 Key strengths
12.1.2.3.2 Strategic choices
12.1.2.3.3 Weaknesses & competitive threats
12.1.3 JOHNSON & JOHNSON SERVICES, INC.
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 MnM view
12.1.3.3.1 Key strengths
12.1.3.3.2 Strategic choices
12.1.3.3.3 Weaknesses & competitive threats
12.1.4 CONVATEC INC.
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.4.3.1 Product launches
12.1.4.3.2 Deals
12.1.4.4 MnM view
12.1.4.4.1 Key strengths
12.1.4.4.2 Strategic choices
12.1.4.4.3 Weaknesses & competitive threats
12.1.5 BOSTON SCIENTIFIC CORPORATION
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.3.1 Deals
12.1.5.4 MnM view
12.1.5.4.1 Key strengths
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses & competitive threats
12.1.6 MEDTRONIC
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.6.3 Recent developments
12.1.6.3.1 Product approvals
12.1.7 TELEFLEX INCORPORATED
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.8 BECTON, DICKINSON AND COMPANY (BD)
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.9 CARDINAL HEALTH
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.10 HOLLISTER INCORPORATED
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.10.3 Recent developments
12.1.10.3.1 Product launches
12.1.11 COOK GROUP
12.1.11.1 Business overview
12.1.11.2 Products offered
12.1.12 LABORIE
12.1.12.1 Business overview
12.1.12.2 Products offered
12.1.12.3 Recent developments
12.1.12.3.1 Other developments
12.2 OTHER PLAYERS
12.2.1 WELLSPECT HEALTHCARE
12.2.2 CALDERA MEDICAL
12.2.3 DYNAREX CORPORATION
12.2.4 ADVACARE PHARMA
12.2.5 MRK HEALTHCARE PVT. LTD.
12.2.6 ADVIN HEALTH CARE
12.2.7 CLINIMED LIMITED
12.2.8 STERIMED GROUP
12.2.9 KIMBERLY-CLARK CORPORATION (KCWW)
12.2.10 INCONTROL MEDICAL
12.2.11 ZEPHYR SURGICAL IMPLANTS
12.2.12 FLEXICARE (GROUP) LIMITED
12.2.13 STRYKER
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS